Lakewood-Amedex Biotherapeutics Inc. (NASDAQ:LABT) Sees Significant Decline in Short Interest

Lakewood-Amedex Biotherapeutics Inc. (NASDAQ:LABT) was the target of a significant decline in short interest during the month of May. As of May 29th, there was short interest totaling 39,018 shares, a decline of 73.7% from the May 14th total of 148,551 shares. Based on an average daily volume of 4,357,454 shares, the short-interest ratio is currently 0.0 days.

Lakewood-Amedex Biotherapeutics Price Performance

LABT stock traded up $0.04 during midday trading on Friday, hitting $0.77. The company’s stock had a trading volume of 299,775 shares, compared to its average volume of 2,963,649. Lakewood-Amedex Biotherapeutics has a 1 year low of $0.59 and a 1 year high of $9.82.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen cut Lakewood-Amedex Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 30th.

Lakewood-Amedex Biotherapeutics Company Profile

We are a biotechnology company focused on leveraging unique, pioneering science to address unmet needs in the treatment of infectious diseases, improving patient outcomes, and significantly reducing the threat posed by antibiotic-resistant bacterial strains, including methicillin resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococci species (VRE), and others. Antimicrobial resistance (AMR) represents a growing global health crisis, being directly responsible for 1.27 million deaths annually and contributing to nearly 5 million deaths worldwide.